Tectonic Therapeutic (TECX)
NASDAQ:TECX
Want to see TECX full AI Analyst Report?
Top Page
Tectonic Therapeutic
(NASDAQ:TECX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$29.00
▼(-1.73% Downside)
Action:ReiteratedDate:04/24/26
The score is held back primarily by pre-revenue operations with widening losses and persistent cash burn, partially offset by a strong, low-debt balance sheet. Technically, longer-term trend support is positive but near-term momentum is soft. Valuation is less supportive due to negative earnings and no indicated dividend, while recent corporate events modestly improve governance and strategic capacity.
Positive Factors
Low leverage and strong capitalization
The very low debt load and materially expanded equity and assets provide durable financial flexibility for multi-year R&D. This reduces near-term refinancing risk, supports continued clinical investment, and preserves optionality for partnerships or opportunistic M&A without forcing immediate dilutive financing.
Negative Factors
Pre-revenue business model
With no commercial revenue, the company lacks internal cash generation and is fully dependent on external funding for operations. This creates ongoing financing reliance, amplifies execution risk from clinical setbacks, and leaves long-term commercial sustainability unproven until assets reach the market.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and strong capitalization
The very low debt load and materially expanded equity and assets provide durable financial flexibility for multi-year R&D. This reduces near-term refinancing risk, supports continued clinical investment, and preserves optionality for partnerships or opportunistic M&A without forcing immediate dilutive financing.
Read all positive factors
Tectonic Therapeutic (TECX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$508.28M
Dividend YieldN/A
Average Volume (3M)218.48K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS Growth50.73%
CountryUS
Employees51
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.03
Shares Outstanding18,776,627
10 Day Avg. Volume179,666
30 Day Avg. Volume218,480
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.58
Forecast
1Y Price Target
$82.67Price Target Upside180.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.88
Revenue Forecast (FY)N/A
Tectonic Therapeutic Business Overview & Revenue Model
Company Description
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform ...
How the Company Makes Money
null...
Tectonic Therapeutic Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -71.48M | -56.23M | -41.19M | -31.03M | -8.12M |
| Net Income | -74.15M | -57.98M | -42.82M | -32.18M | -8.93M |
Balance Sheet | |||||
| Total Assets | 261.04M | 152.91M | 39.40M | 47.21M | 32.88M |
| Cash, Cash Equivalents and Short-Term Investments | 253.80M | 141.24M | 28.77M | 35.97M | 28.06M |
| Total Debt | 1.28M | 3.30M | 4.34M | 5.79M | 1.05M |
| Total Liabilities | 9.71M | 12.13M | 124.03M | 92.86M | 47.84M |
| Stockholders Equity | 251.33M | 140.78M | -84.64M | -45.65M | -14.96M |
Cash Flow | |||||
| Free Cash Flow | -60.29M | -59.24M | -40.96M | -97.47M | -14.58M |
| Operating Cash Flow | -60.08M | -59.08M | -40.68M | -97.21M | -12.45M |
| Investing Cash Flow | -138.00K | -156.00K | -279.00K | -267.00K | -2.12M |
| Financing Cash Flow | 173.35M | 171.71M | 33.75M | 262.00K | 41.42M |
Tectonic Therapeutic Technical Analysis
Positive
29.51
Price Trends
27.88
Positive
24.06
Positive
21.76
Positive
Market Momentum
0.34
Positive
49.55
Neutral
38.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECX, the sentiment is Positive. The current price of 29.51 is below the 20-day moving average (MA) of 30.07, above the 50-day MA of 27.88, and above the 200-day MA of 21.76, indicating a neutral trend. The MACD of 0.34 indicates Positive momentum. The RSI at 49.55 is Neutral, neither overbought nor oversold. The STOCH value of 38.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TECX.
Tectonic Therapeutic Risk Analysis
Tectonic Therapeutic disclosed 78 risk factors in its most recent earnings report. Tectonic Therapeutic reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tectonic Therapeutic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.05B | 3.16 | 1.71% | ― | ― | 90.50% | |
52 Neutral | $508.28M | -5.15 | -26.87% | ― | ― | 50.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $279.41M | -4.58 | 88.31% | ― | 36.75% | 27.97% | |
49 Neutral | $304.64M | 3.92 | 53.18% | ― | ― | ― | |
48 Neutral | $420.81M | -63.66 | -67.33% | ― | ― | 29.16% | |
42 Neutral | $43.98M | -1.59 | -83.02% | ― | ― | 9.75% |
* Healthcare Sector Average
TECX
Tectonic Therapeutic
27.07
6.21
29.77%
OMER
Omeros
14.56
7.21
98.10%
ABEO
Abeona Therapeutics
5.34
-1.22
-18.60%
MREO
Mereo Biopharma Group Plc
0.28
-2.31
-89.34%
FHTX
Foghorn Therapeutics
4.76
0.56
13.33%
LXEO
Lexeo Therapeutics, Inc.
5.68
1.75
44.53%
Tectonic Therapeutic Corporate Events
Business Operations and StrategyExecutive/Board Changes
Tectonic Therapeutic Adds Veteran Banker to Board
Positive
Apr 23, 2026
On April 23, 2026, Tectonic Therapeutic announced the appointment of veteran healthcare investment banker Jessica Chutter to its Board of Directors and Audit Committee, effective June 8, 2026, with her term as a Class III director running until th...
Business Operations and StrategyExecutive/Board Changes
Tectonic Therapeutic Announces Leadership Transition and New Chair
Positive
Feb 24, 2026
On February 23, 2026, Tectonic Therapeutic’s board approved expanding its board from six to seven members and appointed veteran biotech executive François Nader as an independent Class III director, effective April 1, 2026, with his ter...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.